TOMORROW is the prenatal test of the Unilabs Medical Genetics Laboratory (CGC Genetics), which detects, in a non-invasive way, the presence of trisomies 21,18 and 13 in fetal DNA as well as numerical changes in sex chromosomes and fetal sex. 

It's known that approximately 10% of the fragments of free DNA circulating in maternal blood originate in the fetus-placental unit. In the non-invasive prenatal study, DNA fragments (fetal placental and maternal) are sequenced and the number of specific sequences for each chromosomes is determined. The sample sequences are subjected to a complex bioinformatics analysis. In pregnancies where the fetus has a trisomy, the corresponding number of fragments of the affected chromosome will be increased. 

TOMORROW is intended for all pregnant women and is especially recommended for: 

• Pregnant women who wish to rule out the presence of the most common aneuploidies in the fetus (21,18,13,X and Y), whithout resorting to invasive tests

• Pregnant women over 35 years old

• Pregnant women at high risk for trisomies 21,18 and 13. 

• Pregnant women with trisomy diagnosed in previous pregnancy 

• Pregnant women with a history of repeated abortions

• Pregnant women who want to know more information about their baby.

Yes, in the acse of twin pregnancy of two fetuses, TOMORROW analyzes the presence of trisomy 21,18 and 13, and it is not possible to detect aneuploidies of sex chromosomes. 

TOMORROW cannot be performed in the case of twin pregnancies greater than two fetuses. 

The study of fetal sex is performed by the presence or absence of the Y chromosome in maternal blood. In case of detection of the Y chromosome in twin pregnancies (2 fetuses), it is not possible to confirm whether one or both fetuses are male. 

If there's a history of a missing fetus, please tick the Request Form. 

Yes, TOMORROW can be performed in case of pregnancy obtained by in vitro fertilization, with donation of own eggs or not. 

If there is a history of a missing fetus, please tick the Request Form. 

TOMORROW is clinically validated to be performed from 10 weeks and 0 days of gestation, determined by DUM, CRL or another clinically appropriate method (equivalent to 8 weeks of fetal age, if determined by the date of conception). 

It's only necessary to take a blood sample (7-10 mL) in STRECK tube (ref: Cell-Free DNA BCT© CE) at any time of the day and without prior preparation. 

Make sure that sample delivery arrives within a maximum of 4 days after collection by: 

CGC Genetics/Centro de Genética Clínica
Rua Sá da Bandeira, 706-1º
4000-432 Porto, Portugal

TOMORROW analyzes the presence of the main fetal aneuploidies: trisomy 21, 18, 13, identifies the fetal sex and detects the sneuploidies of sex chromosomes (Monosomy X, XXX, XXY e XYY).

Possible Results:
• “Not detected”, in case there is a very low probability for the tested aneuploidies;
• “Detected”, in case there is a very increased probability for the tested aneuploidies; 
• Fetal Sex: Female (XX), Male (XY).

In case of a positive result, confirmation by invasive prenatal diagnosis is advised.

In this case, the laboratory offers at no additional cost: a quick QF-PCR analysis, available in 24 to 48 hours, and also a chromosomal analysis (karyotype), in a fetal sample, free of charge. 

It is recommended that no irreversible clinical decision be taken based solely on the result of this test. 

Average response time of 4 working days (maximum 4) and the result will be sent directly to the requesting doctor. 

TOMORROW, like any other type of analysis, has an inherent percentage of error, albeit very low. The combined rate of false positives and false

A false positive means that although the test result is at increased risk ("detected") for a given aneuploidy, it is not actually present in the fetus, but may be present, for example, only in the placenta (mosaicism of the placenta). 

A false negative means that the test result was shown to be of low risk ("not detected"), however, the fetus has one of the tested aneuploidies. This error is one of the least frequent, with a probability of less than 0.03% for trisomies 21, 18 and 13. 

For more information on the clinical studies carried out to date, please consult the list of publication available .

TALK TO US

Email - tomorrow@unilabs.pt

Cellphone Line TOMORROW - 223 326 608